Recent News
Checkmate Pharmaceuticals Partners with The Chase Group for First Critical Hire in Building Their Clinical Development Team
Due to their long-standing relationship, Checkmate’s Chief Medical Officer has again partnered with The Chase Group as he builds his clinical team. Founded in 2015… Continue Reading →
Akcea Therapeutics Turns to The Chase Group to Secure Chief Medical Officer
Akcea Therapeutics is focused on helping patients living with rare diseases by understanding patient and physician needs by bringing transformative medicines to market. Akcea is… Continue Reading →
Partnership With The Chase Group Results in Successful Placement for Eisai Global Oncology Business Unit
The Chase Group is proud to partner with Eisai and support their human health care mission by securing a strong and agile leader for their… Continue Reading →
Akcea Therapeutics Retains The Chase Group to Secure Senior Vice President for Global Medical Affairs
Akcea Therapeutics is driven by determination and focus on addressing the unmet needs and complex medical challenges of patients with serious and rare disorders. As… Continue Reading →
A New Decade, A New Partnership, and Continued Growth for Alexza Pharmaceuticals and The Chase Group
At the crossroads of innovation and advanced technology, Alexza Pharmaceuticals is working to develop products for the acute treatment of underserved medical needs in neuroscience…. Continue Reading →
Aeglea Biotherapeutics Secures Another Executive for their Clinical Development Leadership Team
To support their rapid growth and expanding portfolio of rare disease programs, Aeglea Biotherapeutics retained The Chase Group and successfully secured a new Global Program… Continue Reading →
The Chase Group is Retained to Secure Multiple Roles for the Eli Lilly Global Oncology Medical Affairs Leadership Team
The Chase Group is proud to partner with Eli Lilly and support their commitment to developing innovative, breakthrough medicines that will make a meaningful difference… Continue Reading →
Eisai, Inc. Retains The Chase Group to Build US Medical Affairs Leadership Team
Eisai, Inc.’s partnership with Merck has proven to be successful with the FDA approval of the Keytruda and Lenvima Combination Treatment. With 13 indications for… Continue Reading →